What is HC Wainwright's Estimate for Evolus FY2026 Earnings?

Evolus, Inc. (NASDAQ:EOLS - Free Report) - Investment analysts at HC Wainwright decreased their FY2026 earnings per share estimates for Evolus in a research report issued on Thursday, April 10th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $0.41 for the year, down from their prior estimate of $0.49. HC Wainwright currently has a "Buy" rating and a $27.00 target price on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus' FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.20 EPS and FY2029 earnings at $3.60 EPS.

Other equities analysts have also issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, April 9th. Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th.

Evolus Price Performance

Evolus stock traded down $0.01 during trading hours on Friday, hitting $10.22. 363,825 shares of the company traded hands, compared to its average volume of 865,772. Evolus has a 1-year low of $8.67 and a 1-year high of $17.82. The firm has a market cap of $649.86 million, a P/E ratio of -11.23 and a beta of 0.97. The firm's 50-day simple moving average is $12.78 and its two-hundred day simple moving average is $13.25. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Insiders Place Their Bets

In related news, Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now directly owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,575 shares of company stock worth $794,369. Company insiders own 6.10% of the company's stock.

Institutional Trading of Evolus

A number of institutional investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new position in shares of Evolus during the 4th quarter worth $49,000. IFP Advisors Inc grew its holdings in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after purchasing an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Evolus in the fourth quarter valued at approximately $106,000. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the fourth quarter worth $115,000. Finally, Quantbot Technologies LP bought a new stake in shares of Evolus during the 4th quarter worth $118,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.